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Introduction 
fm~rovements in l'ulmonary care and other refinements in management allow more 
patients WIth cystic fibroSIS (CF) to survive long enough for liver disease to become a limiting 
factor in their life expectancy (1, 2, 3). Since liver transplantation is considered the treatment 
of choice for patients with end-stage liver disease, it is predictable that more patients with CF 
and liver failure will be referred for transplantation. The results after liver transplantation in 
14 patients with CF are reviewed in this report. 
Clinical Material 
Between January, 1981 through May, 1990 3,019 liver transplantations were performed 
at the University of Pittsburgh. Eighteen of these transplants were performed in 14 patients 
(6 adults and 8 children) with CF who had developed end stage liver disease. The first nine 
patients, previously reported in 1989 (3), were done under cyclosporine, prednisone and 
azathioprine inmmunosupression. The last 5 patients were done with the new immunosup-
pressive drug FK506 and low dose prednisone. The patient demographics, including pre- and 
postoperative pulmonary function tests and current patient status, are summarized in table 1 
below. One patient, who received a a double organ transplant (liver and pancreas), is not 
included in the present series. 
Table 1. Patient Demographics, Pulmonary Function, and Current Status 
Patient Age/Sex FVClFBI1 Current Status 
Preoperative Postoperative 
1 23y/M 72/81 109/119 Alive at 7 1/2 yr, working full time 
2 30y/F 62/50 59/43 Died at 27 months 
3 24y/M 105/114 110/105 Alive at 65 months, working full time 
4 15m/F Alive at 60 months, attending school 
5 3y/M Alive at 43 months, attending school 
6 21y/M 77/74 Died at 2 weeks 
7 8y/M 50/38 109/106 Alive at 36 months, attending school 
8 13y/F 81/68 114/101 Alive at 31 months, attending school 
9 18y/F 61/50 81/70 Alive at 31 months, attending college 
10 31y/F 77/66 Died at 5 1 /2 months 
11 6y/M 114/94 Died at 2 weeks 
12 14y/M 86/70 94/83 Alive at 10 months, attending school 
13 12y/M 90/71 Alive at 10 months, attending school 
14 13ylM 53(51 58145 Alive at 2 months. recuperating 
ResullS 
Ten of the 14 recipients are well with normal liver function tests 2 months to 7.5 years 
after liver transplantation. Two patients died in the early postoperative period of sepsis and 
multiple organ failure following retransplantation, one WIth hepatic artery thrombosis (pa-
tient #6) and the other (patient # 11) with severe allograft rejection. A third gravely ill patient 
(patient #10) with advanced liver disease and severe exocrine and endocrine pancreatic 
insufficiency, died with a perfectly functioning graft 6 months after transplantation. The 
patient, who required a femoral embolectomy on the second postoperative day, remained 
ventilatory dependent thereafter and died of respiratory failure. A fourth recipient (pa-
tient #2) died 27 months after transplantation from an unrecognized closed-loop obstructton 
and gangrenous bowel. This patient also had Friederich's ataxia and mental retardation. 
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Di5russion 
Actuarial patient sur-
vival (Kaplan-Meier) for the 14 
patients ill this series is shown 
ill the figure to the left and is 
77.9% at o~l~ar and 68.2% at 
5 years. onary function 
tests were done in eight patients 
before and after transplanta-
tion (see table 1). Forced vital 
capacity (FVC) and fust second 
forced expiratory volume 
(FEV 1) were improved in pa-
tients 1, 7, 8, 9,and 12, and es-
sentially unchanged in patients 
2,3, and 14. 
The long-term patient survival rate of nearly 70% in this series of patients demon-
strates that results for patients with cystic fibrosis are comparable to those reported for other 
established indications for liver transplantation (4). Nevertheless, due to the multisystemic 
nature of CF, these patients are more likely to develop complications in the early postopera-
tive period. Therefore, in order to improve results ill this group of patients, the following 
points should be stressed: 1) the need for meticulous pulmonary toilet in every patient, and 
for early tracheostomy in the patients who require reintubation or reoperation; 2) aggressive 
bowel care and early introduction of parenteral nutrition; and 3) when using cyclosporine, 
which is poorly absorbed in this group of patients, close monitoring of cyclosporine blood 
level and dosage is recommended. Our experience with liver transplantation for CF using 
FK 506 is still smail, but encouraging. 
Mild to moderate pulmonary disease is not a contraindication'to liver transplantation 
in patients with CF. In fact, some improvement in pulmonary function was noted in 5 of the 
8 patients who were tested before and after transplantation. The reason is not clear yet, 
although there are at least two explanations: 1) improved ventilatory mechanics secondary to 
disappearance of ascites, rebuilding of thoracic muscle mass, and relief of fatigue; and 2) 
modulation of the endobronchial inflammation by immunosuppressive agents. 
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